1.
Neurology
; 100(11): 542-543, 2023 03 14.
Artículo
en Inglés
| MEDLINE
| ID: mdl-36914275
2.
J Neuroophthalmol
; 43(4): e356, 2023 Dec 01.
Artículo
en Inglés
| MEDLINE
| ID: mdl-35051982
3.
Ann Neurol
; 90(2): 315-318, 2021 08.
Artículo
en Inglés
| MEDLINE
| ID: mdl-34114269
RESUMEN
Although SARS-CoV-2 vaccines are very safe, we report 4 cases of the bifacial weakness with paresthesias variant of Guillain-Barré syndrome (GBS) occurring within 3 weeks of vaccination with the Oxford-AstraZeneca SARS-CoV-2 vaccine. This rare neurological syndrome has previously been reported in association with SARS-CoV-2 infection itself. Our cases were given either intravenous immunoglobulin, oral steroids, or no treatment. We suggest vigilance for cases of bifacial weakness with paresthesias variant GBS following vaccination for SARS-CoV-2 and that postvaccination surveillance programs ensure robust data capture of this outcome, to assess for causality. ANN NEUROL 2021;90:315-318.